Real-World Safety Analysis Reveals New Adverse Events for Fenfluramine in Rare Epilepsy Syndromes
Key Insights
A comprehensive pharmacovigilance study analyzed 9,868 fenfluramine-related adverse event reports from the FDA database, revealing previously unrecognized safety risks beyond typical side effects.
The analysis identified emerging cardiovascular risks including pericardial effusion (search) and aortic dilatation (search), alongside neurological and behavioral adverse events such as aggression and mood swings.
Gender-specific patterns emerged with males more prone to aortic valve incompetence (search) and females experiencing higher rates of nervous system adverse reactions.
A large-scale pharmacovigilance study has uncovered previously unrecognized adverse events associated with fenfluramine, an old drug repurposed for treating rare epilepsy (search) syndromes. The analysis of nearly 10,000 adverse event reports reveals significant safety signals that extend beyond the drug's known side effect profile, particularly affecting patients with Lennox-Gastaut syndrome (search) (LGS) and Dravet syndrome (search) (DS).
Comprehensive Safety Profile Analysis
Researchers from Meizhou People's Hospital (search) and The Second Affiliated Hospital of Shantou University Medical College (search) analyzed data from the FDA Adverse Event Reporting System (FAERS) database spanning from the third quarter of 2020 to the fourth quarter of 2024. Following data deduplication and screening, the study included 9,868 fenfluramine-related adverse event reports.
The analysis employed four statistical methods—Reporting Odds Ratio (ROR), Bayesian Confidence Propagation Neural Network (BCPNN), Proportional Reporting Ratio (PRR), and Multi-Item Gamma Poisson Shrinker (MGPS)—to ensure accuracy and reliability of the findings.
Emerging Safety Signals Beyond Known Effects
While fenfluramine's typical side effects include seizure, somnolence, lethargy, status epilepticus (search), balance disorder, and sedation, the study identified several emerging risks that warrant clinical attention. These newly recognized adverse events include pericardial effusion (search), crying, pneumonia, oxygen saturation decreased, muscle twitching, insomnia, aggression, agitation, mood swings, urinary retention, and aortic dilatation (search).
The fenfluramine-induced adverse events occurred across 24 system organ classes (SOCs), demonstrating the drug's broad impact on multiple physiological systems.
Gender-Specific Risk Patterns
The analysis revealed notable gender differences in adverse event patterns. Males showed higher susceptibility to aortic valve incompetence (search) and epilepsy (search), while females demonstrated increased propensity for nervous system adverse reactions following fenfluramine treatment.
Syndrome-Specific Safety Profiles
The study identified distinct risk profiles between the two rare epilepsy (search) syndromes treated with fenfluramine. Patients with LGS showed higher risk for mitral valve incompetence (search), constipation, urinary tract infection, fall, lethargy, and atonic seizures after fenfluramine treatment.
In contrast, DS patients demonstrated elevated risk for pyrexia, illness, nasopharyngitis, influenza, decreased appetite, seizure, generalized tonic-clonic seizure, status epilepticus (search), myoclonic epilepsy (search), and aggression.
Clinical Implications for Monitoring
The researchers emphasized that their findings provide valuable evidence on the real-world safety of fenfluramine, suggesting clinicians should place greater emphasis on monitoring adverse effects during treatment. The study specifically recommends that medical staff pay increased attention to cardiac adverse events in LGS patients and nervous system adverse events in DS patients throughout the entire duration of fenfluramine treatment.
The comprehensive nature of this pharmacovigilance study addresses a critical gap in real-world safety data for fenfluramine use in rare epilepsy (search) populations, where limited clinical trial data may overlook rare but significant adverse events.